Understanding Gastroparesis from Ozempic: Symptoms and Long-Term Monitoring

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Guidance to Targeted Exposure Concerns

If you're experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be concerned about gastroparesis. This condition, now highlighted in FDA label updates, can affect long-term digestive health. Building on decades of drug safety research, this page outlines the symptoms to track and what monitoring involves.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where a delay in the emptying of a solid meal is documented. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology includes slowing of gastric emptying as part of its glucose-lowering mechanism. However, this effect can become pathological in some patients, contributing to the development or exacerbation of gastroparesis. Reported adverse effects from clinical trials indicate that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 32.7% of patients on Ozempic 0.5 mg and 36.4% on Ozempic 1 mg, compared to 15.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and persistent or severe cases may indicate drug-induced gastroparesis. Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which slows gastric motility. While this effect is intended to improve glycemic control, it can lead to delayed gastric emptying that becomes clinically significant, especially in susceptible individuals. The label does not explicitly list gastroparesis as a warning, but the high rates of gastrointestinal adverse reactions suggest a potential for this condition. The label includes a warning for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address gastroparesis.

Legal Considerations and Statute of Limitations in New York

Risk anchors for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information does not contain a specific warning about gastroparesis, which may affect claims of inadequate warning. Settlement-related considerations for patients in New York must account for the statute of limitations, which generally requires filing a lawsuit within a certain period from the date of injury or discovery of harm. In New York, the statute of limitations for personal injury claims is typically three years from the date of injury, but this can vary based on the specifics of the case, including when the injury was discovered or should have been discovered. The timeline between exposure to Ozempic and documented harm is critical; patients who developed gastroparesis after starting Ozempic should document the onset of symptoms and any medical diagnoses. The gastrointestinal adverse reactions often occur during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), which may help establish a temporal relationship. For settlement purposes, patients should gather medical records showing diagnosis of gastroparesis, prescription records for Ozempic, and any communications with healthcare providers about symptoms. The lack of a specific gastroparesis warning in the label may strengthen claims that the manufacturer failed to adequately warn about this risk. However, the high incidence of gastrointestinal adverse reactions documented in clinical trials could be used to argue that the risk was known or should have been known. Patients should consult with a legal professional experienced in pharmaceutical litigation to assess their individual circumstances and ensure compliance with New York's statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims is typically three years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means patients must file a lawsuit within three years of recognizing the link between their gastroparesis and Ozempic use. It is crucial to consult with an attorney to determine the exact deadline based on individual circumstances.

Does Ozempic's label warn about gastroparesis?

No, the prescribing information for Ozempic does not contain a specific warning about gastroparesis. However, it does report high rates of gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, which overlap with gastroparesis symptoms. The lack of a direct warning may be relevant in legal claims alleging inadequate warning. For detailed label information, refer to the DailyMed entry (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.